What is OmniCyte?
OmniCyte operates as a specialized preclinical biotechnology entity, primarily focused on the advancement of targeted cancer therapeutics. At the core of its operations is a proprietary Immuno-Oncology Platform Technology, which utilizes recombinant targeted immunomodulators to address high-acuity indications, including ovarian cancer and small cell lung cancer. By bridging the gap between laboratory research and clinical application, OmniCyte addresses critical unmet needs in the oncology sector. The company maintains a robust research and development infrastructure, supported by a seasoned management team and a strategic network of scientific advisors dedicated to improving patient outcomes through precision medicine.
How much funding has OmniCyte raised?
OmniCyte has raised a total of $20K across 1 funding round:
Debt
$20K
Debt (2021): $20K with participation from PPP
Key Investors in OmniCyte
PPP
Public-Private Partnership
Connecticut Innovations
A venture capital firm specializing in early-stage and growth-stage investments within the Connecticut technology and life sciences ecosystem.
Angel Investors
Private individual investors providing early-stage capital and strategic mentorship to high-growth biotechnology ventures.
What's next for OmniCyte?
With the recent influx of capital, OmniCyte is expected to prioritize the maturation of its lead candidates through rigorous preclinical validation and early-stage clinical trials. The firm's roadmap involves scaling its Immuno-Oncology Platform to broaden its therapeutic reach across diverse cancer indications. Furthermore, the company will likely focus on strengthening its intellectual property portfolio and fostering strategic partnerships to facilitate future commercialization efforts. As the organization moves deeper into its growth phase, the focus will remain on achieving key regulatory milestones and demonstrating the efficacy of its immunomodulatory approach in complex clinical environments.
See full OmniCyte company page
